Core Insights - Cardinal Health's accelerating specialty strategy is central to its earnings expansion, with adjusted EPS guidance for fiscal 2026 raised to $10.15-$10.35, indicating a 23-26% year-over-year growth [1][10] Financial Performance - The Pharmaceutical and Specialty Solutions segment is driving momentum, benefiting from strong demand for brand and specialty drugs, leading to significant profit growth supported by a favorable product mix and cost management [2] - Cardinal Health expects specialty revenues to exceed $50 billion in fiscal 2026, indicating substantial growth in this higher-margin segment [3][10] - The company has raised its fiscal 2026 adjusted EPS guidance, reflecting strong operational execution and continued demand across its pharmaceutical platform [1][10] Strategic Initiatives - A key component of the growth strategy is the rapid expansion of Cardinal Health's specialty ecosystem, including partnerships with physician practices through MSO platforms [4][6] - The acquisition of Solaris Health enhances Cardinal Health's capabilities in the urology specialty, further expanding its footprint [4] - The biopharma services business, including the Sonexus patient-support platform, is gaining traction, reinforcing Cardinal Health's role in the specialty value chain [5][6] Industry Context - Competitors McKesson and Cencora are also expanding into specialty pharmaceuticals, with McKesson reporting double-digit revenue and EPS growth driven by oncology services [7][8] - Cencora reported 12% operating income growth and 9% EPS growth, largely due to its U.S. Healthcare Solutions segment and specialty drug demand [9] Valuation and Estimates - Cardinal Health's shares have gained 5.2% over the past six months, outperforming the industry average of 1.4% [12] - The company trades at a forward price-to-earnings ratio of 19.45, above the industry average and its five-year median of 13.46 [13] - The Zacks Consensus Estimate for fiscal 2026 earnings implies a 25.1% rise from the previous year [14]